Last10K.com

Eiger Biopharmaceuticals, Inc. (EIGR) SEC Filing 8-K Material Event for the period ending Monday, February 6, 2023

Eiger Biopharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1762239 Ticker: EIGR

View differences made from one to another to evaluate Eiger Biopharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Eiger Biopharmaceuticals, Inc..

Continue

Assess how Eiger Biopharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Eiger Biopharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information
Ticker: EIGR
CIK: 1305253
Form Type: 8-K Corporate News
Accession Number: 0001193125-23-032696
Submitted to the SEC: Fri Feb 10 2023 4:32:01 PM EST
Accepted by the SEC: Fri Feb 10 2023
Period: Monday, February 6, 2023
Industry: Biological Products No Disgnostic Substances
Events:
  1. Event for Officers

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/eigr/0001193125-23-032696.htm